Related Experiment Video
Updated: Jan 16, 2026
On-Chip Endothelial Inflammatory Phenotyping
Published on: July 21, 2012
Barbatic acid inhibits inflammatory responses and endothelial dysfunction in hypertension by regulating HIF1A/FLT1
Xu-Zhao Li1, Zhen-Tao Lv1, Xiang Yu1
1College of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guian new area, 550025, PR China.
Insights
Barbatic acid shows potential for treating hypertension by reducing inflammation and endothelial dysfunction. This study confirms its effectiveness in reducing blood pressure and improving organ damage in hypertensive models.
Area of Science:
- Cardiovascular Research
- Pharmacology
- Bioinformatics
Background:
- Hypertension is a major global health risk, driving cardiovascular and cerebrovascular mortality.
- Barbatic acid exhibits potential antihypertensive properties, but its mechanisms require further elucidation.
- Understanding barbatic acid's action is crucial for developing novel hypertension therapies.
Purpose of the Study:
- To investigate the therapeutic potential of barbatic acid in hypertension.
- To elucidate the underlying mechanisms of barbatic acid's antihypertensive effects.
- To validate findings using cellular and animal models.
Main Methods:
- Bioinformatics analysis of a biolabel-led research model.
- Establishment of cellular (Ang II) and animal (L-NAME) hypertension models.
- In vitro (HUVEC proliferation) and in vivo (blood pressure, tissue pathology) experiments.
Main Results:
- Bioinformatics identified ten key biolabels, with HIF1A and FLT1 as primary targets involved in inflammation and endothelial dysfunction.
- Barbatic acid enhanced HUVEC proliferation and modulated ten biolabels and downstream targets in vitro.
- Barbatic acid reduced blood pressure, ameliorated tissue damage, and inhibited HIF1A/FLT1 levels in hypertensive mice.
Conclusions:
- Barbatic acid effectively treats hypertension by targeting the HIF1A/FLT1 pathway.
- The compound inhibits inflammatory responses and improves endothelial dysfunction in hypertension.
- Findings validate the biolabel research model and support barbatic acid as a therapeutic agent.
Abstract:
Hypertension is a prevalent cardiovascular and cerebrovascular condition encountered in clinical practice. It has emerged as a significant global public health challenge and is the leading risk factor for mortality. Barbatic acid has a pharmacological basis for preventing and treating hypertension, including mechanisms such as diuresis and anti-inflammatory effects. However, its therapeutic potential and mechanism of action remain incompletely understood. The purpose of this study is to investigate the therapeutic potential and mechanisms of action of barbatic acid in the treatment of hypertension. Based on the biolabel-led research model, bioinformatics was employed to conduct a comprehensive analysis of the therapeutic potential, advantages, and mechanisms of action of barbatic acid in treating hypertension. Ang II was utilized to establish a hypertensive cellular model, while L-NAME was employed to create an animal model of hypertension, thereby validating the findings from the biolabel analysis. Bioinformatics indicates that ten biolabels are implicated in the anti-hypertensive mechanism of barbatic acid. The primary targets are HIF1A and FLT1, which primarily contribute to inflammatory responses and endothelial dysfunction. Cell experiments demonstrate that barbatic acid can effectively enhance the proliferation ability of HUVECs and adjust the levels of ten biolabels and downstream targets. Animal experiments demonstrate that barbatic acid can effectively reduce blood pressure in hypertensive mice, significantly ameliorate associated pathological damage in the heart, kidney, and thoracic aorta tissues, and inhibit HIF1A/FLT1 levels in these mice, thereby improving the inflammatory response and endothelial dysfunction. The verification confirmed the analytical results of the biolabel research model. Barbatic acid has the capacity to inhibit the inflammatory response and endothelial dysfunction in hypertension by mediating the HIF1A/FLT1 pathway.
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
01:25Antihypertensive Drugs: Direct Renin Inhibitors
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:26Atherosclerosis III: Management